Armstrong Angus, Isalan Mark
Department of Life Sciences, Imperial College London, London, United Kingdom.
Imperial College Centre for Synthetic Biology, Imperial College London, London, United Kingdom.
Front Bioeng Biotechnol. 2024 Sep 18;12:1437301. doi: 10.3389/fbioe.2024.1437301. eCollection 2024.
Over the past 2 decades, rapid advances in synthetic biology have enabled the design of increasingly intricate and biologically relevant systems with broad applications in healthcare. A growing area of interest is in designing bacteria that sense and respond to endogenous disease-associated signals, creating engineered theranostics that function as disease surveyors for human health. In particular, engineered cells hold potential in facilitating greatly enhanced temporal and spatial control over the release of a range of therapeutics. Such systems are particularly useful for targeting challenging, under-drugged disease targets in a more nuanced manner than is currently possible. This review provides an overview of the recent advances in the design, delivery, and dynamics of bacterial theranostics to enable safe, robust, and genetically tractable therapies to treat disease. It outlines the primary challenges in theranostic clinical translation, proposes strategies to overcome these issues, and explores promising future avenues for the field.
在过去的二十年里,合成生物学的迅速发展使得人们能够设计出越来越复杂且与生物学相关的系统,并在医疗保健领域有着广泛的应用。一个日益受到关注的领域是设计能够感知并响应内源性疾病相关信号的细菌,从而创造出作为人类健康疾病监测器的工程化治疗诊断系统。特别是,工程化细胞在极大地增强对一系列治疗药物释放的时空控制方面具有潜力。与目前可行的方式相比,此类系统对于以更细微的方式靶向具有挑战性、药物治疗不足的疾病靶点尤为有用。本综述概述了细菌治疗诊断系统在设计、递送和动力学方面的最新进展,以实现安全、稳健且具有遗传可操作性的疾病治疗。它概述了治疗诊断临床转化中的主要挑战,提出了克服这些问题的策略,并探索了该领域未来有前景的发展方向。